Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. have successfully closed the business combination.
Hyperliquid Strategies Inc's common stock will start trading on Nasdaq under the ticker symbol "PURR" on December 3.
Sonnet BioTherapeutics Holdings, Inc. will continue to operate as a wholly-owned subsidiary of Hyperliquid Strategies Inc.
Business Combination Completion
The business combination between Hyperliquid Strategies Inc, Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC, and sponsors has been finalized.
Trading Debut
Hyperliquid Strategies Inc's common stock will trade on Nasdaq as "PURR" starting December 3, 2025.
Leadership
David Schamis will serve as the Chief Executive Officer of Hyperliquid Strategies Inc, leading a board of directors including prominent industry figures.
- The business combination allows U.S. equity investors to access the HYPE token through a digital asset treasury strategy.
- Hyperliquid's blockchain and decentralized exchange have gained significant traction in the finance industry, attracting large trading volumes.
- Investors now have the opportunity to engage directly in the Hyperliquid ecosystem through a publicly traded vehicle.
The completion of this business combination marks a significant milestone for Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc., opening new investment opportunities in the rapidly growing digital asset space.